Regulatory Lilly bags FDA okay for Wegovy pill rival orforglipron PharmaphorumEli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.RegulatoryMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk’s first-to-market Wegovy pill. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo RivalryNext: FDA approves Lilly obesity pill, triggering battle with Novo Nordisk Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
